Citing a lack of scientific evidence, an influential advisory panel has declined to recommend that older Americans receive ongoing cognitive screening as part of their medical care.
“Alzheimer’s disease (Alzheimer’s), an ultimately fatal form of dementia, is the sixth leading cause of death in the United States, accounting for 3.6% of all deaths in 2014.” – Centers for Disease Control and Prevention
After decades of effort and untold millions invested in the search for an effective treatment for Alzheimer’s, the disease remains unchecked and rampant. Most recently, the New York Times reported that researchers declared defeat after the failure of yet another experimental drug designed to fight the formation of the disease’s signature amyloid plaque in the brain.
A Phase 2 clinical trial testing Annovis Bio’s oral therapy ANV401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review by the study’s independent Data Safety Monitoring Board (DSMB).
Dementia—it’s one of the most dreaded diseases of our time. About 5.8 million people are currently living with Alzheimer’s disease, the most common form of dementia. And that number is expected to skyrocket to 14 million by 2050.
Being Patient spoke with Dr. Laura Lewis about her research into the effects of deep sleep on brain health and cleansing.
The National Institutes of Health (NIH) has awarded a $4.8-million grant to support a project designed to discover how the ApoE4 gene variant, a known genetic risk factor for late-onset Alzheimer’s disease, induces neurodegeneration.
Two experimental drugs failed to prevent or slow mental decline in a study of people who are virtually destined to develop Alzheimer’s disease at a relatively young age because they inherited rare gene flaws.
Scientists in London have identified a type of genetic mutation that appears to protect against late-onset Alzheimer’s disease.
Patients with inflammatory diseases such as rheumatoid arthritis or psoriasis have a higher risk of developing Alzheimer’s disease, which can be reduced by treatment with tumor necrosis factor (TNF) inhibitors.